KOBO Biotech

KOBO Biotech Current Liabilities

The Current Liabilities of KOBO Biotech (531541.BO) as of Oct 23, 2026 is 1.68 B INR. In the previous year, Current Liabilities was 1.66 B INR — a change of 1.17% (higher).

Current Liabilities

1.68 BINR

YoY

1.17%

Last updated:

Current Liabilities of KOBO Biotech is 2024 1.68 B INR. Current Liabilities of KOBO Biotech was 2023 1.66 B INR. It decreases by 1.17% higher compared to the previous year.

The KOBO Biotech Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
2.07 B INR
Jan 1, 2018
2.42 B INR
Jan 1, 2019
2.66 B INR
Jan 1, 2020
2.84 B INR
Jan 1, 2021
2.99 B INR
Jan 1, 2022
1.63 B INR
Jan 1, 2023
1.66 B INR
Jan 1, 2024
1.68 B INR
The KOBO Biotech Current Liabilities history
YEARCurrent LiabilitiesYoY
1.68 BINR+1.17%
1.66 BINR+1.58%
1.63 BINR-45.41%
2.99 BINR+5.23%
2.84 BINR+6.72%
2.66 BINR+10.12%
2.42 BINR+16.70%
2.07 BINR+16.49%
1.78 BINR+8.46%
1.64 BINR-37.74%
2.64 BINR+2.75%
2.56 BINR+38.92%
1.85 BINR+87.58%
984.20 MINR+108.25%
472.60 MINR+97.25%
239.60 MINR+167.71%
89.50 MINR+6.42%
84.10 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

KOBO Biotech Stock analysis

What does KOBO Biotech do? Kobo Biotech Ltd. focuses on manufacturing active pharmaceutical ingredients (APIs)/bulk drugs. The company operates within the pharmaceuticals sector, producing bulk drugs for the industry. Its primary market segment consists of pharmaceutical manufacturers seeking reliable API suppliers. The firm's Solapur site in India is currently inactive, with no operational activities ongoing there. The company's revenue streams derive from the sale of manufactured APIs and bulk drugs to pharmaceutical companies. These products are essential components in the production of finished pharmaceutical formulations. Kobo Biotech Ltd. serves as a key supplier within the pharmaceutical supply chain, providing critical raw materials to its clients. The business model centers on bulk drug manufacturing, with the company acting as a supplier to other pharmaceutical firms. There are no additional product lines or services mentioned beyond API and bulk drug production. The firm's focus remains strictly on the manufacturing of active pharmaceutical ingredients and bulk drugs for the pharmaceutical industry. KOBO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KOBO Biotech stock

Current Liabilities of KOBO Biotech is 1.68 B INR in 2024.

Current Liabilities of KOBO Biotech changed from 1.66 B INR to 1.68 B INR, representing a 1.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities KOBO Biotech since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's KOBO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — KOBO Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — KOBO Biotech